Bristol-Myers Squibb Company operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Bristol-Myers Squibb Company with three other
companies in this sector in UNITED STATES :
sales of $45.80 billion
of which 100%
was pharmaceutical products),
Merck & Co. , Inc.
of which 90%
was Merck Pharmaceutical), and
of which 26%
During the second
quarter of 2021, sales at Bristol-Myers Squibb Company totalled
an increase of 15.5%
from the $10.13 billion in sales at the company during the second quarter of 2020.
During the first two
quarters of 2021, sales totalled $22.78 billion, which is
than through the first two quarters of 2020.
During the previous 26 quarters, sales at Bristol-Myers Squibb Company have increased compared with the same quarter in the previous year.
There appears to be at least some degree of seasonality in the sales at Bristol-Myers Squibb Company: during 8 of the previous 9
years, sales were highest during the fourth quarter.
The exception to this was during 2012, when the
first quarter was the best quarter, accounting for
30% of sales (during that same year, the
fourth quarter accounted for 24% of sales).
During the year ended December of 2020, sales at
Bristol-Myers Squibb Company were $42.52 billion.
increase of 62.6%
versus 2019, when the company's sales were $26.15 billion.
This was the fifth consecutive year of sales increases at Bristol-Myers Squibb Company
(and since 2015, sales have increased a total of 157%).
Sales of Prioritized Brands-Revlimid saw an increase
that was more than double the company's growth rate: sales were up
831.9% in 2020, from
$1.30 billion to $12.11 billion.
Not all segments of Bristol-Myers Squibb Company experienced an increase in sales in 2020:
sales of Other Brands fell 21.4% to $1.32 billion.
Bristol-Myers Squibb Company also experienced decreases in sales in
Prioritized Brands-Opdivo (down 2.9% to $6.99 billion)